Global Assessment of New Molecular Diagnostic Infectious Disease Panels

A molecular diagnostic assay provider sought to better understand the global market, testing workflow, price, and required content and potential revenue for several molecular diagnostic infectious disease panels and to develop strategies to best position the new panels for commercial success.

Approach & Results
Working collaboratively with its client, Life Science Strategy Group consultants conducted 70 in-depth phone interviews and Internet surveys with infectious disease specialists and laboratorians in the US, Europe and Asia. Utilizing LSSG’s extensive contact database and diagnostic expertise, the consulting team validated current and future market size and growth, indentified how new diagnostic assays may be incorporated into existing workflows, determined assay price sensitivity and required and differentiating assay content for GI, fungal and CNS infectious disease assay panels. The client has incorporated LSSG’s insights into its product development program and commissioned a follow-on engagement to assess 3 new molecular diagnostic infectious disease panels.